… Briefly, volunteers aged 40–75 years and with impaired glucose metabolism were recruited
from Kuopio area. Glucose metabolism was one of the primary endpoints in this study and, …

… altered in the smaller S- and M-HDL-P, with a reduction in … L-HDL-P the relative CE content
decreased and the TG content increased. Ezetimibe therapy differentially impacted the HDL …

… catabolism as well as the activity of enzymes involved in HDL metabolism [32]. However, …
Advanced glycation of apolipoprotein AI impairs its anti-atherogenic properties. Diabetologia, …

… Moreover, HDLs also have anti-diabetic properties [28], which may indirectly contribute to
their anti-atherogenic properties. It is thus difficult to assess causality in a clinical setting under …

… A proposed anti-atherogenic mechanism of adiponectin involves its ability to promote
cholesterol efflux. We performed a systematic review of the role of adiponectin in cholesterol efflux …

… HDL protein and lipid cargo resulting in HDL dysfunction. Established and investigational
drugs designed to affect lipid metabolism and to increase HDL-… its anti-atherogenic properties. …

… in HDL-C. EVOO has been also reported to promote cholesterol efflux by HDL, improving
HDL … In conclusion, although EVOO may have possible anti-atherogenic properties, the real …

… The results of recent studies demonstrate that HDL … HDL and LDL 1 subfractions are known
anti-atherogenic fractions, small dense LDL 3–7 subfractions have atherogenic properties [16…

… and/or associate to an amelioration of HDL anti-atherogenic properties in patients with RA.
A key … metabolism. As for LDL, tocilizumab might modulate HDL composition, reducing HDL …

… This disease is considered to be a metabolic disease that is not only largely found in
advanced … The equation: Atherogenic index (AI) = (TC-HDL-C)/HDL-C was used to calculate AI …